CYP2D6 genotypes in association with steady state plasma concentrations of active metabolites of tamoxifen in patients with breast cancer.

被引：0
|
作者：
Lim, H.
Lee, H.
Lee, K.
Lee, E.
Jang, I.
Ro, J.
机构：
[1] Natl Canc Ctr, Res Inst & Hosp, Gyeonggi, South Korea
[2] Natl Canc Ctr, Gyeonggi, South Korea
[3] Seoul Natl Univ, Coll Med, Seoul, South Korea
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2006年 / 24卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：36S / 36S
页数：1
相关论文
共 50 条
  • [31] Effect of CYP2D6 and CYP2C9 genotypes on fluoxetine and norfluoxetine plasma concentrations during steady-state conditions
    Adrián LLerena
    Pedro Dorado
    Roland Berecz
    Antonio P. González
    Eva M. Peñas-LLedó
    European Journal of Clinical Pharmacology, 2004, 59 : 869 - 873
  • [32] First Results From a Study Analyzing CYP2D6 Genotypes and Tamoxifen Metabolites in a Canadian Population With Endocrine Responsive Breast Cancer
    Sousa, B.
    Nasim, S.
    Cole, D.
    Wong, B.
    Hill, K.
    Vandenberghe, H.
    Ueng, S.
    Romaschin, A.
    Warner, E.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S381 - S381
  • [33] Impact of the CYP2D6 phenotype on the outcome of breast cancer patients treated with tamoxifen
    Dorado, Pedro
    Penas-Lledo, Eva
    LLerena, Adrian
    PHARMACOGENOMICS, 2013, 14 (06) : 606 - 606
  • [34] Clinical Trial: CYP2D6 Related Dose Escalation of Tamoxifen in Breast Cancer Patients With Iranian Ethnic Background Resulted in Increased Concentrations of Tamoxifen and Its Metabolites
    Khalaj, Zahra
    Baratieh, Zohreh
    Nikpour, Parvaneh
    Schwab, Matthias
    Schaeffeler, Elke
    Mokarian, Fariborz
    Khanahmad, Hossein
    Salehi, Rasoul
    Muerdter, Thomas E.
    Salehi, Mansoor
    FRONTIERS IN PHARMACOLOGY, 2019, 10
  • [35] The influence of CYP2D6 and CYP3A5 pharmacogenetics on pharmacokinetics of tamoxifen and its metabolites in Asian breast cancer patients
    Chowbay, B.
    Lim, J. S. L.
    Singh, O.
    Ng, R. C. H.
    Wong, N. S.
    Lee, E. J. D.
    EJC SUPPLEMENTS, 2010, 8 (07): : 175 - 175
  • [36] The Impact of CYP2D6*4 on the Survival of Tamoxifen Treated Breast Cancer Patients
    Al Matrafi, Abdullah
    BRITISH JOURNAL OF PHARMACOLOGY, 2023, 180 : 1345 - 1346
  • [37] CYP2D6 Genotype Predicts Tamoxifen Discontinuation and Prognosis in Patients With Breast Cancer
    He, Wei
    Grassmann, Felix
    Eriksson, Mikael
    Eliasson, Erik
    Margolin, Sara
    Thoren, Linda
    Hall, Per
    Czene, Kamila
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06) : 548 - +
  • [38] Differential effects of CYP2D6 genotypes and antidepressants on tamoxifen
    Jin, Y
    Desta, Z
    Stearns, V
    Ward, B
    Skaar, T
    Storniolo, AM
    Nguyen, A
    Hayes, DF
    Flockhart, DA
    DRUG METABOLISM REVIEWS, 2004, 36 : 114 - 114
  • [39] Association between CYP2D6*10 genotype and survival of breast cancer patients receiving tamoxifen treatment
    Xu, Y.
    Sun, Y.
    Yao, L.
    Shi, L.
    Wu, Y.
    Ouyang, T.
    Li, J.
    Wang, T.
    Fan, Z.
    Fan, T.
    Lin, B.
    He, L.
    Li, P.
    Xie, Y.
    ANNALS OF ONCOLOGY, 2008, 19 (08) : 1423 - 1429
  • [40] Re: CYP2D6 Genotyping and the Use of Tamoxifen in Breast Cancer
    Province, Michael A.
    Klein, Teri E.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2014, 106 (02):
12345